Paper36367013
Tracking the progressive spread of the SARS-CoV-2 Omicron variant in Italy, December 2021 to January 2022.
Stefanelli P and 26 others. Euro Surveill, 2022. Cited by 36 papers, by iCite.
Cite this record
ConductScience Library. Tracking the progressive spread of the SARS-CoV-2 Omicron variant in Italy, December 2021 to January 2022. Papers, record 36367013. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36367013
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Tracking the progressive spread of the SARS-CoV-2 Omicron variant in Italy, December 2021 to January 2022.
- PubMed
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| SARS-CoV-2 | Major topic |
| COVID-19 | Major topic |
| Humans | |
| Vaccination | |
| Base Sequence |
Source PubMed
References16
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35411997 | Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa. | Trop Med Int Health | 2022 | https://conductscience.org/library/papers/35411997 | PubMed |
| 2 | 35264324 | Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. | BMJ | 2022 | https://conductscience.org/library/papers/35264324 | PubMed |
| 3 | 35016199 | Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. | Nature | 2022 | https://conductscience.org/library/papers/35016199 | PubMed |
| 4 | 35514304 | COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants - surveillance results from southern Sweden, December 2021 to March 2022. | Euro Surveill | 2022 | https://conductscience.org/library/papers/35514304 | PubMed |
| 5 | 33750783 | Infectivity, susceptibility, and risk factors associated with SARS-CoV-2 transmission under intensive contact tracing in Hunan, China. | Nat Commun | 2021 | https://conductscience.org/library/papers/33750783 | PubMed |
| 6 | 35798890 | SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. | Nat Microbiol | 2022 | https://conductscience.org/library/papers/35798890 | PubMed |
| 7 | 35021005 | SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons. | N Engl J Med | 2022 | https://conductscience.org/library/papers/35021005 | PubMed |
| 8 | 33234640 | Rapid review of available evidence on the serial interval and generation time of COVID-19. | BMJ Open | 2020 | https://conductscience.org/library/papers/33234640 | PubMed |
| 9 | 32720639 | Authors' response: Estimating the generation interval for COVID-19 based on symptom onset data. | Euro Surveill | 2020 | https://conductscience.org/library/papers/32720639 | PubMed |
| 10 | 37133863 | Evaluation of Waning of SARS-CoV-2 Vaccine-Induced Immunity: A Systematic Review and Meta-analysis. | JAMA Netw Open | 2023 | https://conductscience.org/library/papers/37133863 | PubMed |
| 11 | 36524247 | Estimation of the incubation period and generation time of SARS-CoV-2 Alpha and Delta variants from contact tracing data. | Epidemiol Infect | 2022 | https://conductscience.org/library/papers/36524247 | PubMed |
| 12 | 35623379 | COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England. | Lancet Infect Dis | 2022 | https://conductscience.org/library/papers/35623379 | PubMed |
| 13 | 33767447 | Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. | Nature | 2021 | https://conductscience.org/library/papers/33767447 | PubMed |
| 14 | 35215887 | The Spread of SARS-CoV-2 Variant Omicron with a Doubling Time of 2.0-3.3 Days Can Be Explained by Immune Evasion. | Viruses | 2022 | https://conductscience.org/library/papers/35215887 | PubMed |
| 15 | 34814093 | The early phase of the COVID-19 epidemic in Lombardy, Italy. | Epidemics | 2021 | https://conductscience.org/library/papers/34814093 | PubMed |
| 16 | 35791373 | Intrinsic generation time of the SARS-CoV-2 Omicron variant: An observational study of household transmission. | Lancet Reg Health Eur | 2022 | https://conductscience.org/library/papers/35791373 | PubMed |
Cited by32
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 36 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42082766 | Implications for distancing measures on in-person school and work attendance from Italian post-pandemic social contact data. | Commun Med (Lond) | 2026 | https://conductscience.org/library/papers/42082766 | PubMed |
| 41316388 | Booster dose reshapes SARS-CoV-2 RBD-specific B cell immunity in people living with HIV. | J Transl Med | 2025 | https://conductscience.org/library/papers/41316388 | PubMed |
| 41246331 | Minimal association between Th1-specific responses to COVID-19 vaccines and SARS-CoV-2 breakthrough infections in multiple sclerosis patients receiving disease-modifying therapies. | Front Immunol | 2025 | https://conductscience.org/library/papers/41246331 | PubMed |
| 40977733 | Reduced spike specific T-cell responses in COVID-19 vaccinated subjects undergoing SARS-CoV-2 breakthrough infection. | Front Immunol | 2025 | https://conductscience.org/library/papers/40977733 | PubMed |
| 40464897 | SARS-CoV-2 infection does not affect the outcome of patients with relapsed/refractory large B-cell lymphoma treated with CAR T-cell therapy. | Ann Hematol | 2025 | https://conductscience.org/library/papers/40464897 | PubMed |
| 40332006 | Immune Response Against Recent Omicron Sub-Lineages in Persons with HIV Receiving a Protein-Based or mRNA XBB.1.5 SARS-CoV-2 Booster Vaccine. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40332006 | PubMed |
| 40133656 | Comparative spatial-temporal analysis of SARS-CoV-2 lineages B.1.1.33 and BQ.1.1 Omicron variant across pandemic phases. | Sci Rep | 2025 | https://conductscience.org/library/papers/40133656 | PubMed |
| 40083630 | Pilot study: a descriptive-retrospective analysis of SARS-CoV-2 variants distribution and phylogenesis in the Phlegraean area. | Front Mol Biosci | 2025 | https://conductscience.org/library/papers/40083630 | PubMed |
| 39407950 | Impact and Effectiveness of COVID-19 Vaccines Based on Machine Learning Analysis of a Time Series: A Population-Based Study. | J Clin Med | 2024 | https://conductscience.org/library/papers/39407950 | PubMed |
| 39204049 | Anti-RBD Antibody Levels and IFN-γ-Specific T Cell Response Are Associated with a More Rapid Swab Reversion in Patients with Multiple Sclerosis after the Booster Dose of COVID-19 Vaccination. | Vaccines (Basel) | 2024 | https://conductscience.org/library/papers/39204049 | PubMed |
| 38675876 | Prevalence of Respiratory Viral Infections in Deceased Persons during the COVID-19 Pandemic Season 2021-2022: A Population-Based Observational Study. | Viruses | 2024 | https://conductscience.org/library/papers/38675876 | PubMed |
| 38675795 | Estimating All-Cause Deaths Averted in the First Two Years of the COVID-19 Vaccination Campaign in Italy. | Vaccines (Basel) | 2024 | https://conductscience.org/library/papers/38675795 | PubMed |
| 38455311 | A Comparison Between Omicron and Earlier COVID-19 Variants' Disease Severity in the Milan Area, Italy. | Front Epidemiol | 2022 | https://conductscience.org/library/papers/38455311 | PubMed |
| 38449900 | General infection prevention, mitigation, and control procedures implemented in the university education during the COVID-19 pandemic to achieve classroom attendance: a successful community case study. | Front Public Health | 2023 | https://conductscience.org/library/papers/38449900 | PubMed |
| 38187213 | Covid-19 Occupational Risk Incidence and Working Sectors Involved During the Pandemic in Italy. | Saf Health Work | 2023 | https://conductscience.org/library/papers/38187213 | PubMed |
| 38137955 | SARS-CoV-2 in Animal Companions: A Serosurvey in Three Regions of Southern Italy. | Life (Basel) | 2023 | https://conductscience.org/library/papers/38137955 | PubMed |
| 38006015 | Older Age, a High Titre of Neutralising Antibodies and Therapy with Conventional DMARDs Are Associated with Protection from Breakthrough Infection in Rheumatoid Arthritis Patients after the Booster Dose of Anti-SARS-CoV-2 Vaccine. | Vaccines (Basel) | 2023 | https://conductscience.org/library/papers/38006015 | PubMed |
| 37599801 | Estimating SARS-CoV-2 infections and associated changes in COVID-19 severity and fatality. | Influenza Other Respir Viruses | 2023 | https://conductscience.org/library/papers/37599801 | PubMed |
| 37371134 | Facing the Challenges in the COVID-19 Pandemic Era: From Standard Treatments to the Umbilical Cord-Derived Mesenchymal Stromal Cells as a New Therapeutic Strategy. | Cells | 2023 | https://conductscience.org/library/papers/37371134 | PubMed |
| 37254497 | The relative prevalence of the Omicron variant within SARS-CoV-2 infected cohorts in different countries: A systematic review. | Hum Vaccin Immunother | 2023 | https://conductscience.org/library/papers/37254497 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36367013
GET https://conductscience.org/api/papers/v1/36367013/authors?page=2